Lori E Lowes
Overview
Explore the profile of Lori E Lowes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu E, Allan A, Sanatani M, Lewis D, Warner A, Dar A, et al.
BMC Cancer
. 2022 Jul;
22(1):746.
PMID: 35804307
Background: Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. Methods: We prospectively collected CTC...
2.
Kitz J, Lefebvre C, Carlos J, Lowes L, Allan A
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884649
Prostate cancer is the most common cancer in American men and the second leading cause of cancer-related death. Most of these deaths are associated with metastasis, a process involving the...
3.
Kitz J, Goodale D, Postenka C, Lowes L, Allan A
Clin Exp Metastasis
. 2021 Jan;
38(1):97-108.
PMID: 33415568
Circulating tumor cells (CTCs) present an opportunity to detect/monitor metastasis throughout disease progression. The CellSearch® is currently the only FDA-approved technology for CTC detection in patients. The main limitation of...
4.
Lowes L, Hedley B, Sutherland D, Keeney M
Cytometry B Clin Cytom
. 2020 Oct;
100(4):402-405.
PMID: 33009886
No abstract available.
5.
Hedley B, Cheng G, Keeney M, Kern W, Padurean A, Luider J, et al.
Cytometry B Clin Cytom
. 2020 Jul;
100(2):225-234.
PMID: 32667744
Multiparameter flow cytometry plays an important role in the diagnosis, staging, and monitoring of patients with a suspected hematological malignancy. The ClearLLab 10C Panels consist of four reagent panels (B-Lineage...
6.
Medeiros B, Goodale D, Postenka C, Lowes L, Kiser P, Hearn S, et al.
Cancers (Basel)
. 2020 Jan;
12(1).
PMID: 31936750
The lung is one of the deadliest sites of breast cancer metastasis, particularly in patients with triple-negative (TN) disease. We hypothesized that the presence of a TN primary breast tumor...
7.
Kitz J, Lowes L, Goodale D, Allan A
Diagnostics (Basel)
. 2018 May;
8(2).
PMID: 29710776
The majority of cancer deaths occur because of metastasis since current therapies are largely non-curative in the metastatic setting. The use of in vivo preclinical mouse models for assessing metastasis...
8.
Lowes L, Allan A
Adv Clin Chem
. 2018 Jan;
83:121-181.
PMID: 29304900
The majority of cancer-related deaths result from metastasis, the process by which cancer cells escape the primary tumor site and enter into the blood circulation in order to disseminate to...
9.
Lowes L, Goodale D, Xia Y, Postenka C, Piaseczny M, Paczkowski F, et al.
Oncotarget
. 2016 Oct;
7(46):76125-76139.
PMID: 27764810
Metastasis is the cause of most prostate cancer (PCa) deaths and has been associated with circulating tumor cells (CTCs). The presence of ≥5 CTCs/7.5mL of blood is a poor prognosis...
10.
Lowes L, Bratman S, Dittamore R, Done S, Kelley S, Mai S, et al.
Int J Mol Sci
. 2016 Sep;
17(9).
PMID: 27618023
Despite the identification of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) as potential blood-based biomarkers capable of providing prognostic and predictive information in cancer, they have not been incorporated...